[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,318,256
  • Shares Outstanding, K 133,513
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 752 M
  • EBITDA $ 808 M
  • 60-Month Beta 0.31
  • Price/Sales 10.97
  • Price/Cash Flow 109.10
  • Price/Book 37.87

Options Overview Details

View History
  • Implied Volatility 41.69% (+1.34%)
  • Historical Volatility 28.54%
  • IV Percentile 39%
  • IV Rank 48.02%
  • IV High 54.81% on 01/09/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 17) 20.91 (6.98%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 29
  • Volume Avg (30-Day) 433
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 23,815
  • Open Int (30-Day) 23,762
  • Expected Range 278.81 to 320.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.54
  • Number of Estimates 9
  • High Estimate $1.91
  • Low Estimate $1.00
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +396.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
284.28 +4.96%
on 05/11/26
306.03 -2.50%
on 05/06/26
+2.28 (+0.77%)
since 05/01/26
3-Month
284.28 +4.96%
on 05/11/26
343.36 -13.10%
on 04/14/26
-34.53 (-10.37%)
since 02/27/26
52-Week
284.28 +4.96%
on 05/11/26
495.55 -39.79%
on 10/20/25
-6.17 (-2.03%)
since 05/30/25

Most Recent Stories

More News
Alnylam Issues 2025 Corporate Responsibility Report

– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support –

ALNY : 299.23 (-0.91%)
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing...

ALNY : 299.23 (-0.91%)
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – ...

ALNY : 299.23 (-0.91%)
Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:...

ALNY : 299.23 (-0.91%)
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc . (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...

ALNY : 299.23 (-0.91%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 299.23 (-0.91%)
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025)...

ALNY : 299.23 (-0.91%)
Alnylam's Earnings Tomorrow Could Validate the Case That RNAi Has Finally Arrived

Barchart Research What to Expect from ALNY Earnings ALNY Generated April 29, 2026 Current Price $301.19 EPS Estimate $$0.91 Consensus Rating Moderate Buy Average Move 6.06% Alnylam's Earnings Tomorrow...

ALNY : 299.23 (-0.91%)
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday,...

ALNY : 299.23 (-0.91%)
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger...

ALNY : 299.23 (-0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 313.96
2nd Resistance Point 309.82
1st Resistance Point 305.90
Last Price 299.23
1st Support Level 297.84
2nd Support Level 293.70
3rd Support Level 289.78

See More

52-Week High 495.55
Fibonacci 61.8% 414.84
Fibonacci 50% 389.91
Fibonacci 38.2% 364.99
Last Price 299.23
52-Week Low 284.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.